Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1967 2
1968 5
1969 2
1970 10
1971 1
1972 1
1973 4
1974 2
1975 4
1976 12
1977 24
1978 16
1979 14
1980 26
1981 28
1982 58
1983 51
1984 52
1985 60
1986 66
1987 75
1988 69
1989 84
1990 84
1991 83
1992 89
1993 57
1994 55
1995 71
1996 54
1997 64
1998 54
1999 41
2000 54
2001 43
2002 41
2003 20
2004 24
2005 29
2006 40
2007 31
2008 30
2009 27
2010 22
2011 22
2012 22
2013 32
2014 27
2015 15
2016 19
2017 18
2018 12
2019 8
2020 6
2021 9
2022 10
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

1,841 results

Results by year

Filters applied: . Clear all
Page 1
Calcium-channel blocking agents.
Leonard RG, Talbert RL. Leonard RG, et al. Clin Pharm. 1982 Jan-Feb;1(1):17-33. Clin Pharm. 1982. PMID: 6764159 Review.
The role of calcium in the cardiovascular system, and the pharmacology, pharmacokinetics, and studies evaluating the clinical use of three calcium-channel blocking agents--verapamil hydrochloride, nifedipine, and diltiazem hydrochloride--are reviewed. ...It is absorbed wel …
The role of calcium in the cardiovascular system, and the pharmacology, pharmacokinetics, and studies evaluating the clinical use of three c …
Pharmacokinetics of calcium channel blocking agents.
Anderson P. Anderson P. Acta Pharmacol Toxicol (Copenh). 1986;58 Suppl 2:43-57. doi: 10.1111/j.1600-0773.1986.tb02520.x. Acta Pharmacol Toxicol (Copenh). 1986. PMID: 2940799 Review.
Verapamil and nifedipine are the most frequently used calcium channel blocking agents in Sweden at present time. ...Plasma concentration-effect relationships have been established for verapamil in different clinical situations and in a few cases also for nifedipine. …
Verapamil and nifedipine are the most frequently used calcium channel blocking agents in Sweden at present time. ...Plasma concentrat …
Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
McTavish D, Sorkin EM. McTavish D, et al. Drugs. 1989 Jul;38(1):19-76. doi: 10.2165/00003495-198938010-00003. Drugs. 1989. PMID: 2670511 Review.
Although verapamil is a well-established treatment for angina, cardiac arrhythmias and cardiomyopathies, this review reflects current interest in calcium antagonists as anti-hypertensive agents by focusing on the role of verapamil in hypertension. ...Sustained relea …
Although verapamil is a well-established treatment for angina, cardiac arrhythmias and cardiomyopathies, this review reflects current …
N(1) -Methylnicotinamide as Biomarker for MATE-Mediated Renal Drug-Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid.
Müller F, Hohl K, Keller S, Schmidt-Gerets S, Deutsch B, Schuler-Metz A, Fromm MF, Stopfer P, Gessner A. Müller F, et al. Clin Pharmacol Ther. 2023 May;113(5):1070-1079. doi: 10.1002/cpt.2849. Epub 2023 Feb 12. Clin Pharmacol Ther. 2023. PMID: 36636898 Clinical Trial.
In trial 2, NMN was investigated after treatment with cocktail alone or with cocktail + inhibitor (cimetidine, a MATE inhibitor; or rifampin, verapamil, or probenecid, inhibitors of other transporters). In trial 1, NMN kinetics in plasma and urine were essentially not affe …
In trial 2, NMN was investigated after treatment with cocktail alone or with cocktail + inhibitor (cimetidine, a MATE inhibitor; or rifampin …
Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators.
Rosei EA, Dal Palù C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Rosei EA, et al. J Hypertens. 1997 Nov;15(11):1337-44. doi: 10.1097/00004872-199715110-00019. J Hypertens. 1997. PMID: 9383184 Clinical Trial.

Normalization of the diastolic blood pressure (to < or = 90 mmHg or to < or = 95 mmHg with a > or = 10% decrease) was achieved for 69.3% of the verapamil and 66.9% of the chlorthalidone group. A decrease in heart rate (by 5.8%) occurred in members of the verapa

…

Normalization of the diastolic blood pressure (to < or = 90 mmHg or to < or = 95 mmHg with a > or = 10% decrease) was achieved for

…
Oral verapamil in paroxysmal supraventricular tachycardia recurrence control: a randomized clinical trial.
Shaker H, Jahanian F, Fathi M, Zare M. Shaker H, et al. Ther Adv Cardiovasc Dis. 2015 Feb;9(1):4-9. doi: 10.1177/1753944714553425. Epub 2014 Oct 8. Ther Adv Cardiovasc Dis. 2015. PMID: 25297337 Free article. Clinical Trial.
Patients in the adenosine-only group did not received any other medications but patients in the adenosine/verapamil group received 40 mg verapamil orally immediately after converting the rhythm to sinus rhythm. ...Two patients in the adenosine-only group experienced …
Patients in the adenosine-only group did not received any other medications but patients in the adenosine/verapamil group received 40 …
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.
Busse D, Templin S, Mikus G, Schwab M, Hofmann U, Eichelbaum M, Kivistö KT. Busse D, et al. Eur J Clin Pharmacol. 2006 Aug;62(8):613-9. doi: 10.1007/s00228-006-0154-7. Epub 2006 Jul 4. Eur J Clin Pharmacol. 2006. PMID: 16823584 Clinical Trial.
METHODS: Eight healthy volunteers received a single oral dose of 120 mg (S)-verapamil, 480 mg (R)-verapamil, 240 mg racemic verapamil (rac-verapamil) or placebo on 4 separate occasions. ...(R)-verapamil but not (S)-verapamil significantly …
METHODS: Eight healthy volunteers received a single oral dose of 120 mg (S)-verapamil, 480 mg (R)-verapamil, 240 mg racemic …
Verapamil and ventricular tachyarrhythmias.
Nguyen NX, Yang PT, Huycke E, Sung RJ. Nguyen NX, et al. Pacing Clin Electrophysiol. 1987 May;10(3 Pt 1):571-8. doi: 10.1111/j.1540-8159.1987.tb04522.x. Pacing Clin Electrophysiol. 1987. PMID: 2440008 Review. No abstract available.
Hydrochlorothiazide and verapamil in the treatment of hypertension. The Verapamil Versus Diuretic (VERDI) Trial Research Group.
Holzgreve H, Distler A, Michaelis J, Philipp T, Wellek S. Holzgreve H, et al. J Cardiovasc Pharmacol. 1991;18 Suppl 6:S33-7. J Cardiovasc Pharmacol. 1991. PMID: 1725915 Clinical Trial.
The efficacy and tolerability of hydrochlorothiazide, sustained-release verapamil, and their combination was compared in patients with mild to moderate hypertension. ...Adding verapamil to hydrochlorothiazide was more effective in lowering blood pressure than adding …
The efficacy and tolerability of hydrochlorothiazide, sustained-release verapamil, and their combination was compared in patients wit …
A Dose-Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis.
Padmapriyadarsini C, Szumowski JD, Akbar N, Shanmugasundaram P, Jain A, Bathragiri M, Pattnaik M, Turuk J, Karunaianantham R, Balakrishnan S, Pati S, Kumar AKH, Rathore MK, Raja J, Naidu KR, Horn J, Whitworth L, Sewell R, Ramakrishnan L, Swaminathan S, Edelstein PH. Padmapriyadarsini C, et al. Clin Pharmacol Ther. 2024 Feb;115(2):324-332. doi: 10.1002/cpt.3108. Epub 2023 Dec 11. Clin Pharmacol Ther. 2024. PMID: 37983978 Free PMC article. Clinical Trial.
Verapamil's mycobacterial efflux pump inhibition also limits Mtb growth in macrophages in the absence of antibiotic treatment. ...Moreover, norverapamil:verapamil, R:S verapamil, and R:S norverapamil AUC ratios were all significantly greater than those …
Verapamil's mycobacterial efflux pump inhibition also limits Mtb growth in macrophages in the absence of antibiotic treatment. …
1,841 results